Last reviewed · How we verify
California Allergy and Asthma Medical Group, Inc. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Mometasone furoate 220 | Mometasone furoate 220 | marketed | ||||
| Mometasone furoate 440 | Mometasone furoate 440 | marketed | Inhaled corticosteroid | Glucocorticoid receptor | Respiratory / Allergy / Immunology |
Therapeutic area mix
- Respiratory / Allergy / Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Chiesi Farmaceutici S.p.A. · 1 shared drug class
- Dey · 1 shared drug class
- Fujian Medical University Union Hospital · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Imperial College London · 1 shared drug class
- Intech Biopharm Ltd. · 1 shared drug class
- Istituto per la Ricerca e l'Innovazione Biomedica · 1 shared drug class
- AstraZeneca · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for California Allergy and Asthma Medical Group, Inc.:
- California Allergy and Asthma Medical Group, Inc. pipeline updates — RSS
- California Allergy and Asthma Medical Group, Inc. pipeline updates — Atom
- California Allergy and Asthma Medical Group, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). California Allergy and Asthma Medical Group, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/california-allergy-and-asthma-medical-group-inc. Accessed 2026-05-17.